Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors

Anthony T.P. Chan, Sydney C.W. Tang
2022 Kidney Research and Clinical Practice  
Progress in the treatment of diabetic kidney disease (DKD) has been modest since the early trials on renin-angiotensin-aldosterone system inhibitors (RAASis). Although sodium-glucose co-transporter 2 inhibitors (SGLT2is) have revolutionized the management of DKD by lowering proteinuria and protecting organs, other novel treatment approaches with good evidence and efficacy that can be used in conjunction with a RAASi or SGLT2i in managing DKD have emerged in the past few years. This review
more » ... ses the evidence for glucagon-like peptide-1 receptor agonist, selective mineralocorticoid receptor antagonist, and selective endothelin A receptor antagonist, emerging treatment options for DKD beyond SGLT2 inhibition.
doi:10.23876/j.krcp.21.285 pmid:35977903 pmcid:PMC9731775 fatcat:qlqktjoyvja2rdwpqochy6y6cq